3-[3-(3-fluorophenyl)prop-2-ynylsulfanyl]-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-[3-(3-fluorophenyl)prop-2-ynylsulfanyl]-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
• 化学式: C₁₇H₁₆FN₃S₂
• 分子量: 345.5
• InChiKey: BCXZGRDMEPIOBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  82.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
  申请人：Chase Pharmaceuticals Corporation

  公开号：US10307409B2

  公开（公告）日：2019-06-04

  A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.

  一种毒蕈碱胆碱能受体激动剂、一种非抗胆碱能止吐药和一种非选择性外周抗胆碱能药的复方制剂，用于治疗中枢神经系统的低胆碱能紊乱。
• Oxybutynin transdermal therapeutic system muscarinic agonist combination
  申请人：CHASE PHARMACEUTICALS CORPORATION

  公开号：US10596139B2

  公开（公告）日：2020-03-24

  Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The pharmaceutical compositions and combinations also allow for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a muscarinic receptor antagonist and a muscarinic receptor agonist.

  含有毒蕈碱受体拮抗剂（如透皮治疗系统中的奥昔布宁）和毒蕈碱受体激动剂（可选择与乙酰胆碱酯酶抑制剂一起使用）的药物组合物和组合物，以及使用这些药物组合物和组合物治疗中枢神经系统低胆碱能疾病（如阿尔茨海默型痴呆症）的方法。本发明的各种药物组合物和组合物可以安全地施用大剂量毒蕈碱受体激动剂，并提高毒蕈碱受体激动剂治疗中枢神经系统低胆碱能疾病的疗效。当乙酰胆碱酯酶抑制剂与毒蕈碱受体拮抗剂和毒蕈碱受体激动剂联合使用时，本发明的药物组合物和复方制剂还能最大限度地向中枢神经系统提供乙酰胆碱。
• OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION
  申请人：Chase Pharmaceuticals Corporation

  公开号：EP3265128A1

  公开（公告）日：2018-01-10
• MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Chase Pharmaceuticals Corporation

  公开号：EP3347011A1

  公开（公告）日：2018-07-18
• MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Chase Pharmaceuticals Corporation

  公开号：EP3347012A1

  公开（公告）日：2018-07-18